一品红: 股票交易异常波动公告

Core Viewpoint - The company reported a significant net loss for the fiscal year 2024, with a net profit attributable to shareholders of -540.39 million yuan and a net profit of -288.94 million yuan after deducting non-recurring gains and losses, indicating financial challenges ahead [1][2]. Group 1: Stock Trading and Financial Performance - The company's stock experienced abnormal trading fluctuations, with a cumulative closing price increase exceeding 30% over three consecutive trading days on May 19, 20, and 21, 2025, as per Shenzhen Stock Exchange regulations [2]. - The board confirmed that there are no undisclosed significant matters that could impact the company's stock price, and previous disclosures do not require correction or supplementation [2][3]. Group 2: Related Transactions and Regulatory Approvals - A proposal regarding the equity of minority shareholders and related transactions is pending approval from the shareholders' meeting, which introduces uncertainty [3]. - The product AR882 has not yet been approved for market sales, and thus has not generated any sales revenue, which will not significantly impact the company's recent performance [3][4]. Group 3: Risk Factors in Pharmaceutical Development - The pharmaceutical development process is characterized by high investment, high risk, and high potential returns, with long timelines and multiple stages that are susceptible to unpredictable factors [4].